Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Is It Too Early to Predict the Failure of Natalizumab in NMO?
Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.
Prevalence and Impact of Pain in Adults Aging With a Physical Disability: Comparison to a US General Population Sample.
Managing Disability in Progressive Multiple Sclerosis.
Validity and reliability of the Greek version of the Modified Fatigue Impact Scale in multiple sclerosis patients.
Abnormal brain iron metabolism in irp2 deficient mice is associated with mild neurological and behavioral impairments.
Multiple sclerosis susceptibility in a Brazilian sample, HLA and CIITA genes.
Inadvertent foley catheterization of the ureter.
Orientational ordering of carotenoids in myelin membranes resolved by polarized Raman microspectroscopy.
Magnetic Resonance Spectroscopy: A Possible In Vivo Marker of Disease Progression for Multiple Sclerosis?
Natalizumab (BG00002) Re-Initiation of Dosing. (STRATA)
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation.
Gene expression analysis of histamine receptors in peripheral blood mononuclear cells from individuals with clinically-isolated syndrome and different stages of multiple sclerosis.
Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis.
Acute effects of walking, cycling, and yoga exercise on cognition in persons with relapsing-remitting multiple sclerosis without impaired cognitive processing speed.
Information processing speed and attention in multiple sclerosis: Reconsidering the Attention Network Test (ANT).
Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients.
Therapeutics to Promote CNS Repair: A Natural Human Neuron-Binding IgM Regulates Membrane-Raft Dynamics and Improves Motility in a Mouse Model of Multiple Sclerosis.
Fatigue and its association with sleep disorders, depressive symptoms and anxiety in patients with multiple sclerosis.
Temporal aspects of visual perception in demyelinative diseases.
Unemployment among women with multiple sclerosis: the role of coping and perceived stress and support in the workplace.
Caregiving in Multiple Sclerosis and Quality of Life: A Meta-synthesis of Qualitative Research.
Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis.
MS as a gateway disease.
KATP Channel Opener Diazoxide Prevents Neurodegeneration: A New Mechanism of Action via Antioxidative Pathway Activation.
Pages
« first
‹ previous
…
365
366
367
368
369
370
371
372
373
…
next ›
last »